BioMarin to Include Additional Phase 3 Trial for Hemophilia A Gene Therapy – Specialty Pharmacy Times
|
BioMarin to Include Additional Phase 3 Trial for Hemophilia A Gene Therapy
Specialty Pharmacy Times An additional phase 3 study investigating the novel gene therapy BMN 270 for the treatment of hemophilia A will be added as part of BioMarin Pharmaceutical's development plan for the drug. Two separate studies will be conducted to examine the safety … |
